Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV
The company recently raised US $ 2.25 million seed round and the app was CE-Certified as a medical device in Europe
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
The approval follows the pivotal Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT cut the risk of radiological progression or death by 46% compared to placebo plus ADT
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
Subscribe To Our Newsletter & Stay Updated
